189 related articles for article (PubMed ID: 8695276)
1. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
Luparello C; Del Rosso M
Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
[TBL] [Abstract][Full Text] [Related]
2. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
4. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
[TBL] [Abstract][Full Text] [Related]
5. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
Longstaff C; Merton RE; Fabregas P; Felez J
Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
[TBL] [Abstract][Full Text] [Related]
7. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
8. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
10. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
11. Urokinase induces receptor mediated brain tumor cell migration and invasion.
MacDonald TJ; DeClerck YA; Laug WE
J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
[TBL] [Abstract][Full Text] [Related]
12. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
13. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
Hjertner O; Qvigstad G; Hjorth-Hansen H; Seidel C; Woodliff J; Epstein J; Waage A; Sundan A; Börset M
Br J Haematol; 2000 Jun; 109(4):815-22. PubMed ID: 10929035
[TBL] [Abstract][Full Text] [Related]
14. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
15. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
17. EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases.
Guerrero J; Santibañez JF; González A; Martínez J
Exp Cell Res; 2004 Jan; 292(1):201-8. PubMed ID: 14720519
[TBL] [Abstract][Full Text] [Related]
18. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Huang S; New L; Pan Z; Han J; Nemerow GR
J Biol Chem; 2000 Apr; 275(16):12266-72. PubMed ID: 10766865
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
